Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Film financing and film production can be long, slow processes. But deals for distribution rights may be struck up fast and furious, as seen from distribution interest in buzz movies at film festivals. This happened with Precious: Based on the Novel Push by Sapphire, a film about a young African-American mother in Harlem that won both the grand jury prize and audience award in drama at the Sundance Film Festival in January 2009. Hurried negotiations for the film distribution rights to Push has led to multi-suit litigation ' and a recent Manhattan federal district court ruling that may help define when there's a binding distribution deal.
Features
Highlights of the latest franchising news from around the country.
Features
Highlights of the latest franchising cases from around the country.
It's time to take a leap and leave behind your firm's entrenched identity as a legal services provider: to succeed, you must start thinking of your firm as a media company.
Features
At long last, marketing and communications can take center stage and become the key indicator by which law firms can measure their success ratio.
Features
Highlights of the latest intellectual property news from around the country.
Features
There are many ways that accepting a 2(f) notation can come back and haunt you once litigation has commenced.
Features
Taking a page from the Federal Circuit's own analysis of the issue, we will examine the who, what, when, where (and why) of the decision in <i>Exergen Corporation v. Wal-Mart Stores, Inc.</i>
Features
Less than two months before the Supreme Court is scheduled to review the Federal Circuit's <i>en banc</i> decision in <i>In re Bilski</i> that found Bilski's business method claims unpatentable under 35 U.S.C. § 101, the Federal Circuit held in <i>Prometheus Labs., Inc. v. Mayo Collaborative Servs.</i> (Fed. Cir. 2009) that claims to a diagnostic method are patent-eligible subject matter. The Federal Circuit reversed the district court's decision and held that Prometheus' personalized medicine claims satisfied the machine or transformation test set out in <i>Bilski</i>.
